Detection of LRRC32/GARP in Human PBMCs stimulated to induce Tregs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) stimulated to induce Regulatory T Cells (Tregs) treated with 10 μg/mL Anti-CD3, 5 μg/mL Anti-CD28, 10 ng/mL Recombinant Human TGF‑ beta 1 (Catalog # 240-B), and 20 ng/mL Recombinant Human IL‑2 (Catalog # 202-IL) for 48 hours were stained with Mouse Anti-Human LAP TGF‑ beta 1 APC‑conjugated Monoclonal Antibody (Catalog # FAB2463A) and either (A) Rat Anti-Human LRRC32/GARP Alexa Fluor® 488‑conjugated Monoclonal Antibody (Catalog # FAB6055G) or (B) Rat IgG2A Alexa Fluor 488 Isotype Control (Catalog # IC006G). View our protocol for Staining Membrane-associated Proteins.
Preparation and Storage
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Protect from light. Do not freeze.
12 months from date of receipt, 2 to 8 °C as supplied.
Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant), is an 80 kDa type I transmembrane glycoprotein (1). Mature human LRRC32 consists of a 608 amino acid (aa) extracellular domain (ECD) that contains 22 leucine‑rich repeats, a 21 aa transmembrane segment, and a 14 aa cytoplasmic domain (2, 3). Within the ECD, human LRRC32 shares approximately 80% aa sequence identity with mouse and rat LRRC32. LRRC32 is widely expressed during embryogenesis and on adult platelets (4, 5). Human LRRC32 is identified as a lineage specific key receptor for human T cells. It is selectively expressed on activated FOXP3+ regulatory T cells (Treg) (6-10). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of naïve T cells (6-8). LRRC32 binds directly to the TGF-beta latency associated peptide (LAP) and tethers latent TGF-beta on the surface of activated Treg cells (9, 10). The presentation of TGF-beta on Tregs contributes to their ability to suppress naïve T cell proliferation (11).
Battaglia, M. and M.G. Roncarolo (2009) Eur. J. Immunol. 39:3296.
Ollendorff, V. et al. (1994) Cell Growth Differ. 5:213.
Bella, J. et al. (2008) Cell Mol Life Sci. 65:2307.
Roubin, R. et al. (1996) Int. J. Dev. Biol. 40:545.
Macaulay, I.C. et al. (2007) Blood 109:3260.
Wang, R. et al. (2008) PloS ONE 3:e2705.
Wang, R. et al. (2009) Proc. Natl. Acad. Sci. 106:13439.
Probst-Kepper, M. et al. (2009) J. Cell. Mol. Med. 13:3343.
Tran, D.Q. et al. (2009) Proc. Natl. Acad. Sci. 106:13445.
Stockis, J. et al. (2009) Eur. J. Immunol. 39:3315.
Vignali, D.A. et al. (2008) Nat. Rev. Immunol. 8:523.
Leucine-rich Repeat Containing 32/Glycoprotein A Repetitions Predominant
Entrez Gene IDs:
2615 (Human); 434215 (Mouse)
D11S833E; D11S833Eleucine-rich repeat-containing protein 32; GARP; GARPGarpin; Garpin; Glycoprotein A repetitions predominantgarpin; leucine rich repeat containing 32
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.